RxDoctor Payments Data

Gregory Polar, DO

Dermatology · West Nyack, NYNPI 1992948939

Payments from drug & device makers

$24,589in general payments, 2019–2025

Across 1,072 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$4K
  • AbbVie$3K
  • Incyte Corporation$2K
  • Sanofi$2K
  • Johnson & Johnson$1K
  • LEO Pharma Inc.$1K
  • plus $10K from 26 others

What the payments were for

  • Consulting fees$3,40314%
  • Speaking & faculty fees$5452%
  • Food & beverage$19,40079%
  • Education$8844%
  • Gifts$3571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,589 in reported general payments places this provider in the 85th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$130,208
Medicare patients
319
Services billed
2,147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa11$223,958
OpzeluraRuxolitinib Phosphate39$77,755
Dupixent PenDupilumab18$64,848
Clobetasol Propionate58$2,607
Tacrolimus19$2,250
Ketoconazole93$1,523
Betamethasone Dipropionate34$1,284
Clindamycin Phosphate18$967
Metronidazole15$844
Gentamicin Sulfate16$840
Tretinoin15$838
Triamcinolone Acetonide68$592
Ciclopirox12$472
Fluocinonide11$357
Mupirocin30$325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$2,128$77,75539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,151 dermatology providers in New York.

Other dermatology in West Nyack

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →